Join Meridian Bioscience at the Next Generation Dx Summit, hosted by the Cambridge Healthtech Institute which unites global leaders driving innovation in diagnostics. This year’s program covers a wide range of breakthrough areas—from liquid biopsy and infectious disease testing to companion diagnostics, clinical microbiology, and decentralized testing.
Webinar
Despite gaining traction in diagnostics, molecular Point-of-Care (POC) tests face challenges related to accessibility, stability, and ease of workflow.
Due to infrastructure limitations, especially in remote areas, there is often a lack of necessary resources for appropriately storing reagents, and complex workflows are frequently difficult to implement in non-laboratory settings.
Webinar
With over 12 different types of human papilloma virus (HPV) that can cause cancer, it is the leading cause of cervical cancer in women. The HPV/Pap smear co-test has improved the accuracy of cervical cancer screening; however the test has several limitations. Recent advancements in molecular diagnostics have led to the development of genotype-specific HPV tests that accurately detect and differentiate HPV strains, including high-risk oncogenic types such as HPV-16 and HPV-18.
Blog Article
What happens when the speed of point‑of‑care testing (POCT) meets the depth of next‑generation sequencing (NGS)? In this insightful article, we explores how advances in microfluidics, miniaturized NGS enzymes, and AI-driven portability are breaking down the traditional divide between rapid diagnostics and comprehensive genomic insight. Discover how this next‑gen synergy promises faster, smarter, and more precise molecular diagnostics—right where and when they’re needed most.